Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | JNJ-75348780 |
Trade Name | |
Synonyms | |
Drug Descriptions |
JNJ-75348780 is a bi-specific antibody targeting CD3 and CD22, which may lead to cytotoxic immune response against B-cell tumors (NCI Thesaurus). |
DrugClasses | CD22 Immune Cell Therapy 15 CD3 Antibody 99 |
CAS Registry Number | NA |
NCIT ID | C178408 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
JNJ-75348780 | JNJ-75348780 | 0 | 1 |
JNJ-75348780 + JNJ-87801493 | JNJ-75348780 JNJ-87801493 | 0 | 1 |